Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation.

Citation data:

Cancer research, ISSN: 1538-7445, Vol: 77, Issue: 18, Page: 4745-4754

Publication Year:
2017
Captures 25
Readers 25
Social Media 7
Tweets 7
Citations 3
Citation Indexes 3
PMID:
28754673
DOI:
10.1158/0008-5472.can-17-0164
Author(s):
Yin, Yi; Li, Rui; Xu, Kangling; Ding, Sentai; Li, Jeffrey; Baek, GuemHee; Ramanand, Susmita G; Ding, Sam; Liu, Zhao; Gao, Yunpeng; Kanchwala, Mohammed S; Li, Xiangyi; Hutchinson, Ryan; Liu, Xihui; Woldu, Solomon L; Xing, Chao; Desai, Neil B; Feng, Felix Y; Burma, Sandeep; de Bono, Johann S; Dehm, Scott M; Mani, Ram S; Chen, Benjamin P C; Raj, Ganesh V Show More Hide
Publisher(s):
American Association for Cancer Research (AACR)
Tags:
Medicine; Biochemistry, Genetics and Molecular Biology
Most Recent Tweet View All Tweets
article description
In prostate cancer, androgen deprivation therapy (ADT) enhances the cytotoxic effects of radiotherapy. This effect is associated with weakening of the DNA damage response (DDR) normally supported by the androgen receptor. As a significant number of patients will fail combined ADT and radiotherapy, we hypothesized that DDR may be driven by androgen receptor splice variants (ARV) induced by ADT. Investigating this hypothesis, we found that ARVs increase the clonogenic survival of prostate cancer cells after irradiation in an ADT-independent manner. Notably, prostate cancer cell irradiation triggers binding of ARV to the catalytic subunit of the critical DNA repair kinase DNA-PK. Pharmacologic inhibition of DNA-PKc blocked this interaction, increased DNA damage, and elevated prostate cancer cell death after irradiation. Our findings provide a mechanistic rationale for therapeutic targeting of DNA-PK in the context of combined ADT and radiotherapy as a strategy to radiosensitize clinically localized prostate cancer. .